430

Terns Pharmaceuticals INC

+$2.2B

Net Activity

Institutions Holding

323

Popularity Rank

#1845

Avg Weight

0.82%

Total Value

$7.2B

Ownership Trend

323 institutions currently hold 430, with 244 net buyers and 111 net sellers this quarter.

Institutional Moves

Institutional Moves (Q1 2026)

Majority Increased

Based on recent trading activity

Net Selling Institutions

111

Net Buying Institutions

244

Key Holders

View all 323 holding institutions

Quarterly Activity

Recent Activity

+$13.2B

Total Buy Value

$2.5B

Total Sell Value

New buy128
Trim55
Add116
Sold out56

244

Net Buyers

111

Net Sellers

Insider Trading (Form 4)

Form 144 Pre-Sale Notices

No Form 144 planned sale filings in the last 90 days

Beneficial Ownership (13D/13G)

No Schedule 13D/13G filings for this ticker

Material Events (8-K)

No Form 8-K filings for this ticker

FAQ

Who are the top institutional investors holding TERNS PHARMACEUTICALS INC (430)?
Major stakeholders currently include BlackRock, Inc. ($504.5M), Morgan Stanley ($340.0M), Avoro Capital Advisors LLC ($300.2M). Based on the latest 13F filings, there are a total of 323 tracked investment funds and institutions maintaining positions in 430.
What is the overall institutional sentiment toward 430 recently?
Institutional sentiment appears Bullish (Net Buying). During the most recent reporting quarter, the stock experienced a net inflow of $2.2B, driven by 244 managers accumulating shares while 111 reduced their exposure.
Which institutions have been selling or reducing their 430 positions?
In the latest period, 55 funds trimmed their holdings, and 56 managers completely exited their positions. The aggregate reported sell value was $2.5B.
Are there any notable investors adding 430 to their portfolios?
Yes, buying activity remains notable. 128 institutions opened new positions in {ticker}, and 116 existing holders added to their shares. The total reported buy value for the quarter amounted to $13.2B.

Related Stocks